ट्राइहेक्सीफेनिडिल के इंटरैक्शन

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (इप्राट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Avoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs. (एक्लिडिनियम लेबल, दवाओं के इंटरैक्शन)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (क्विनिडिन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

• Other Conditions Exacerbated by Anticholinergic Adverse Reactions : Use is not recommended in patients with autonomic neuropathy, hyperthyroidism, cardiac disease, hiatal hernia, etc. (ग्लाइकोपाइरोलेट लेबल, चेतावनियां और सावधानियां)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (ग्लूकागॉन लेबल, दवाओं के इंटरैक्शन)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Avoid administration of SPIRIVA RESPIMAT with other anticholinergic-containing drugs. (टियोट्रोपियम लेबल, दवाओं के इंटरैक्शन)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

…(HR) b or Serotonin Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension… (ट्रैनिलसाइप्रोमिन लेबल, दवाओं के इंटरैक्शन)

Usage of MOTOFEN ® in recommended doses is not likely to cause prominent anticholinergic side effects, but MOTOFEN ® should be avoided in patients in whom anticholinergic drugs are contraindicated. (डाइफेनॉक्सिन और एट्रोपिन लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (पोटैशियम साइट्रेट लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (मेटोक्लोप्रामाइड लेबल, चेतावनियां और सावधानियां)

Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs. (यूमेक्लिडिनियम लेबल, दवाओं के इंटरैक्शन)

Avoid administration of Umeclidinium and Vilanterol ELLIPTA with other anticholinergic-containing drugs. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (रिवास्टिग्मिन लेबल, दवाओं के इंटरैक्शन)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Neuroleptic Malignant Syndrome A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with dose reduction or discontinuation of trihexyphenidyl. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (इनकोबोटुलिनमटॉक्सिनA लेबल, चेतावनियां और सावधानियां)

Caution is, therefore, advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution with other drugs having anticholinergic properties. β-adrenergic agents Caution is advised in the co-administration of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution and other sympathomimetic agents due to the increased risk… (इप्राट्रोपियम और सैल्बुटामोल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Oxybutynin chloride extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis and intestinal atony. (ऑक्सीब्यूटिनिन लेबल, चेतावनियां और सावधानियां)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (ओनाबोटुलिनमटॉक्सिनA लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (कार्बिडोपा लेबल, चेतावनियां)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

The recent use of other drugs that cause CNS depression or EPS symptoms (e.g., alcohol, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics) may also increase the risk for these serious CNS reactions [see Warnings and Precautions ( 5.1 , 5.5 )] . (ट्राइमेथोबेंज़ामाइड लेबल, चेतावनियां और सावधानियां)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Trospium chloride extended-release capsules, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis. (ट्रोस्पियम लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic agents: may affect the gastrointestinal absorption of various drugs; may also increase certain actions or side effects of other anticholinergic drugs (7) (डाइसाइक्लोमिन लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic effects of quinidine: Monitor for worsening in myasthenia gravis and other sensitive conditions. (डेक्सट्रोमेथॉर्फन और क्विनिडिन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Darifenacin extended-release tablets, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as severe constipation, ulcerative colitis, and myasthenia gravis. (डैरिफेनासिन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (ड्यूटेट्राबेनाज़िन लेबल, चेतावनियां और सावधानियां)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (नियोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (पाइरिडोस्टिग्मिन लेबल, चेतावनियां और सावधानियां)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (पाइलोकार्पिन लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (प्रोकेनामाइड लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Trihexyphenidyl should be administered with caution in hot weather, especially when given concomitantly with other atropine-like drugs to the chronically ill, alcoholics, those who have central nervous system disease, or those who do manual labor in a hot environment. (ट्राइहेक्सीफेनिडिल लेबल, चेतावनियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Urinary Retention in Adult Patients With Bladder Outlet Obstruction The use of Toviaz, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction, including patients with urinary retention, may result in further urinary retention and kidney injury. (फेसोटेरोडिन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (बेनाज़ेप्रिल और हाइड्रोक्लोरोथायज़ाइड लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (बोटुलिनम टॉक्सिन टाइप A लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

• Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (मिराबेग्रॉन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

The usual dose of either trihexyphenidyl or levodopa may need to be reduced during concomitant therapy, since concomitant administration may increase drug-induced involuntary movements (See DOSAGE AND ADMINISTRATION ). (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (वाल्बेनाज़िन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (विबेग्रॉन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (सक्सिनिलकोलिन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (सुगैमाडेक्स लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Urinary Retention The use of Solifenacin succinate tablets, like other antimuscarinic drugs, in patients with clinically significant bladder outlet obstruction including patients with urinary retention, may result in further urinary retention and kidney injury. (सोलिफेनासिन लेबल, चेतावनियां और सावधानियां)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Concurrent use of alcohol or other CNS depressants with trihexyphenidyl may cause increased sedative effects. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Drug Interactions Cannabinoids, barbiturates, opiates, and alcohol may have additive effects with trihexyphenidyl, and thus, an abuse potential exists. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (गैलेंटामिन लेबल, दवाओं के इंटरैक्शन)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (टोलकैपोन लेबल, सावधानियां)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

When benztropine mesylate is given concomitantly with phenothiazines, haloperidol, or other drugs with anticholinergic or antidopaminergic activity, patients should be advised to report gastrointestinal complaints, fever or heat intolerance promptly. (बेंज़ट्रोपिन लेबल, चेतावनियां)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

NAMZARIC may interfere with anticholinergic medications. (मेमेंटिन और डोनेपेज़िल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Monoamine oxidase inhibitors and tricyclic antidepressants possessing significant anticholinergic activity may intensify the anticholinergic effects of antidyskinetic agents because of the secondary anticholinergic activities of these medications. (ट्राइहेक्सीफेनिडिल लेबल, दवाओं के इंटरैक्शन)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (सेविमेलिन लेबल, दवाओं के इंटरैक्शन)